Eli LillyLLY
Daily Market Briefing
Latest briefing
Eli Lilly's stock rises as Q1 earnings beat expectations and 2026 guidance is raised.
Eli Lilly reported strong first-quarter 2026 results, with adjusted earnings per share of $8.55, surpassing the consensus estimate of $7.06. The company also raised its full-year earnings guidance to a range of $35.50 to $37.00 per share, up from the previous $33.50 to $35.00. This positive performance is driven by robust sales of its GLP-1 drugs, Mounjaro and Zepbound, which saw significant year-over-year growth.
Previous briefings
Eli Lilly's Jaypirca (pirtobrutinib) approved as first-line treatment for CLL/SLL
Eli Lilly's Jaypirca (pirtobrutinib) has received FDA approval as a first-line treatment for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not been previously treated and do not have a known 17p deletion. This approval is expected to expand the drug's market potential and strengthen Lilly's oncology portfolio.
Eli Lilly's stock rises 1.3% amid FDA approvals and expanded partnerships
Eli Lilly's stock experienced a 1.3% increase following recent FDA approvals and strategic partnerships. The FDA granted orphan-drug designation to olomorasib for pancreatic cancer, potentially providing development incentives and future market exclusivity. Additionally, the FDA expanded Jaypirca’s approval into the first-line CLL/SLL setting, broadening Lilly’s commercial cancer portfolio. Lilly also completed early trials for a new basal-insulin candidate and advanced Phase 1 development of eltrekibart. The company expanded its Gate Bioscience drug-discovery collaboration, potentially worth over $870 million, and joined a $120 million financing for healthcare company General Medicine. Analysts remain broadly bullish, with a “Moderate Buy” consensus and an average price target of $1,311.96. However, the stock's premium valuation and potential U.S. price pressure on Mounjaro and Zepbound present risks.
Eli Lilly's stock rises 3.56% after FDA approves Onswik insulin and InnoCare deal
Eli Lilly's stock surged 3.56% following the FDA's approval of Onswik, a once-weekly basal insulin for type 2 diabetes, and the announcement of a research and license agreement with InnoCare Pharma valued over $3 billion. These developments are expected to enhance Lilly's position in the diabetes treatment market and expand its oncology pipeline.
Eli Lilly's stock rises 0.76% to $1,179.27 amid positive clinical trial data.
Eli Lilly's stock price increased by 0.76% to $1,179.27 following the release of promising Phase 3b clinical trial data for its psoriasis and obesity treatments. The data demonstrated significant improvements in patients using the combination of Taltz and Zepbound compared to Taltz alone.
Eli Lilly's stock drops 4.64% amid market volatility on October 8, 2026.
Eli Lilly's stock declined by 4.64% on October 8, 2026, amid broader market fluctuations. The company continues to make significant strides in its pipeline, including advancements in its obesity and oncology treatments. However, concerns about valuation and potential pricing pressures on key drugs like Mounjaro and Zepbound persist.
Eli Lilly's stock rises 2.7% to $1,188.72 amid positive clinical trial results.
Eli Lilly's stock experienced a 2.7% increase, closing at $1,188.72, following the announcement of positive results from the Phase 3 BRUIN CLL-314 clinical trial. The trial demonstrated that Jaypirca (pirtobrutinib) met its primary endpoint of non-inferiority in overall response rate compared to ibrutinib, with a numerically higher response rate of 87.0% versus 78.5%. Additionally, progression-free survival data trended favorably for pirtobrutinib, indicating a potential 43% reduction in the risk of disease progression or death.
Eli Lilly's Jaypirca approved as first-line treatment for CLL/SLL
Eli Lilly's Jaypirca (pirtobrutinib) has received FDA approval as a first-line treatment for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not been previously treated and do not have a known 17p deletion. This approval is expected to expand the drug's market potential and strengthen Lilly's oncology portfolio.
Eli Lilly's stock rises 0.41% after announcing drug discovery partnership
Eli Lilly's stock experienced a modest increase of 0.41% following the announcement of a new drug discovery partnership with Ginkgo Bioworks. This collaboration aims to enhance Lilly's capabilities in developing innovative therapeutics.
Eli Lilly's Jaypirca approved by FDA for first-line CLL/SLL treatment
Eli Lilly's Jaypirca (pirtobrutinib) has received FDA approval for first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adults without known 17p deletion. This approval is based on positive results from the BRUIN CLL-313 clinical trial, which demonstrated significant improvement in progression-free survival compared to standard treatments.
Eli Lilly's Jaypirca approved as first-line treatment for CLL/SLL patients
Eli Lilly's Jaypirca (pirtobrutinib) has received expanded FDA approval for first-line treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without known 17p deletion. This approval is based on positive results from the BRUIN CLL-313 clinical trial, which demonstrated significant delay in disease progression compared to chemoimmunotherapy.
Eli Lilly's Foundayo shows significant reductions in long-term diabetes risks
Eli Lilly's oral GLP-1 medication, Foundayo (orforglipron), has demonstrated substantial reductions in the predicted 10-year risks of type 2 diabetes and cardiovascular disease. Post-hoc analyses from the Phase 3 ATTAIN-1 trial revealed that the 17.2 mg dose of Foundayo was associated with a 57% reduction in type 2 diabetes risk and an 18% reduction in cardiovascular disease risk compared to placebo. These findings suggest a promising addition to Lilly's portfolio in managing obesity-related health risks.
Eli Lilly's Zepbound shows superior weight loss over Wegovy in new study.
Eli Lilly's Zepbound (tirzepatide) demonstrated greater weight loss compared to Novo Nordisk's Wegovy (semaglutide) in a recent indirect treatment comparison. The study found that Zepbound 15 mg led to an average body weight reduction 4.5% greater than Wegovy HD 7.2 mg over 72 weeks. Additionally, Zepbound 15 mg increased the odds of losing at least 20% of body weight by 3.54 times compared to Wegovy HD.
Eli Lilly's stock rises 3.35% to $1,189.49 after $3.35 billion InnoCare partnership
Eli Lilly's stock increased by 3.35% to $1,189.49 following the announcement of a $3.35 billion partnership with InnoCare Pharma, focusing on cancer and autoimmune disease treatments. This strategic move is expected to enhance Lilly's pipeline and market position in these therapeutic areas.
Eli Lilly's Onswik insulin approval boosts stock to $1,184.38.
Eli Lilly's stock rose to $1,184.38 following the FDA's approval of Onswik, a once-weekly insulin for type 2 diabetes. This approval is expected to enhance the company's position in the diabetes treatment market.
Eli Lilly breaks ground on $6.5B Houston plant to boost pharmaceutical production.
Eli Lilly has initiated construction of a $6.5 billion pharmaceutical manufacturing facility in northeast Houston, marking a significant expansion of the company's production capabilities. The plant is expected to produce active pharmaceutical ingredients, including those for Foundayo, Lilly's oral GLP-1 weight-loss drug. This investment underscores Lilly's commitment to enhancing domestic manufacturing and meeting growing global demand.
Eli Lilly breaks ground on $6.5B Houston plant to boost obesity drug production.
Eli Lilly has commenced construction on a $6.5 billion pharmaceutical manufacturing plant in Houston, Texas. The facility aims to produce active pharmaceutical ingredients, including those for Foundayo, Lilly's oral GLP-1 weight-loss drug. This expansion underscores Lilly's commitment to enhancing its obesity treatment portfolio and strengthening its manufacturing capabilities.
Eli Lilly's $6.5B Houston plant groundbreaking boosts stock outlook.
Eli Lilly has commenced construction on a $6.5 billion pharmaceutical manufacturing plant in Houston, Texas, marking a significant expansion in the company's production capabilities. This strategic move is expected to enhance the supply of active pharmaceutical ingredients, including those for Foundayo, Lilly's oral GLP-1 weight-loss drug, potentially increasing revenue streams and solidifying market position.
Eli Lilly breaks ground on $6.5B Houston plant to boost pharmaceutical production
Eli Lilly has commenced construction on a $6.5 billion pharmaceutical manufacturing plant in northeast Houston, marking a significant expansion of the city's life sciences sector. The 236-acre facility, located in Generation Park, will produce active pharmaceutical ingredients, including for Foundayo, Lilly's oral GLP-1 weight-loss drug. This project is being hailed as a milestone for Texas, with Governor Greg Abbott describing it as the largest active pharmaceutical ingredient initiative in the state’s history. The plant highlights Houston's growing importance in healthcare and pharmaceutical manufacturing and is scheduled for completion by 2030.
Eli Lilly breaks ground on $6.5B Houston plant, expanding pharmaceutical manufacturing.
Eli Lilly has commenced construction on a $6.5 billion pharmaceutical manufacturing plant in northeast Houston, marking a significant expansion of the city's life sciences sector. The 236-acre facility, located in Generation Park, will produce active pharmaceutical ingredients, including for Foundayo, Lilly's oral GLP-1 weight-loss drug. This project is being hailed as a milestone for Texas, with Governor Greg Abbott describing it as the largest active pharmaceutical ingredient initiative in the state’s history. The plant highlights Houston's growing importance in healthcare and pharmaceutical manufacturing and is scheduled for completion by 2030.
Eli Lilly invests $4.5 billion in Indiana manufacturing to boost genetic medicine production.
Eli Lilly has committed an additional $4.5 billion across two of its Indiana manufacturing sites, bringing the total capital expansion in the state since 2020 to over $21 billion. This investment aims to support the production of Foundayo™ (orforglipron), Lilly's first FDA-approved oral weight-loss pill, and retatrutide, an investigational triple hormone receptor agonist for obesity and cardiometabolic diseases. The expansion includes the opening of Lilly Lebanon Advanced Therapies, the company's first dedicated genetic medicine manufacturing facility.
Eli Lilly's Inluriyo and Verzenio combo approved for advanced breast cancer treatment.
Eli Lilly's combination therapy of Inluriyo (imlunestrant) and Verzenio (abemaciclib) has been approved by the U.S. FDA for treating adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer. This approval is expected to enhance Lilly's oncology portfolio and contribute to revenue growth.
Eli Lilly's Inluriyo Receives FDA Approval for Advanced Breast Cancer Treatment
Eli Lilly's Inluriyo, an oral estrogen receptor antagonist, has been fully approved by the U.S. FDA in combination with Verzenio for treating advanced or metastatic breast cancer. This approval is expected to enhance Lilly's oncology portfolio and potentially drive significant revenue growth.
Eli Lilly's stock rises after Berenberg upgrades to 'Buy' with $1,400 price target.
Eli Lilly's stock received a boost as Berenberg Bank upgraded the company to a 'Buy' rating, raising the price target to $1,400 from $1,220. This positive sentiment is further supported by the company's strong performance in the obesity and diabetes treatment sectors.
Eli Lilly's Foundayo captures over 30% of new U.S. oral weight-loss patients
Eli Lilly's oral obesity treatment, Foundayo, has secured more than 30% of new patients in the U.S. market, narrowing the lead of competitor Novo Nordisk's Wegovy. This significant market share gain underscores Foundayo's growing acceptance among patients seeking oral weight-loss solutions.
Eli Lilly's stock price declines by 1.2% amid competitive challenges in obesity treatments.
Eli Lilly's stock experienced a 1.2% decline, closing at approximately $1,232, influenced by competitive developments in the obesity treatment sector. Notably, Novartis' cholesterol drug setback has raised concerns about the efficacy of similar treatments, including Eli Lilly's GLP-1 weight-loss drugs. Additionally, some employers are limiting coverage for weight-loss medications, potentially affecting patient adoption and revenue growth.
Eli Lilly's stock price declines 1.2% amid competitor's drug setback
Eli Lilly's stock experienced a 1.2% decline following a competitor's drug setback. Novartis' cholesterol drug failed to reduce cardiovascular events, raising concerns about the efficacy of similar treatments, including Eli Lilly's.
Eli Lilly's stock declines following Novartis' cholesterol drug setback
Eli Lilly's stock experienced a decline due to a recent setback in the cholesterol drug market. Novartis' pelacarsen failed to reduce cardiovascular events despite lowering harmful cholesterol levels, raising concerns about the efficacy of similar treatments, including those in Eli Lilly's pipeline. This development has introduced uncertainty regarding the future performance of Eli Lilly's cardiovascular drugs.
Eli Lilly's stock drops 2.06% amid Novartis' cholesterol drug trial failure
Eli Lilly's stock declined by 2.06% following Novartis' announcement that its cholesterol drug, pelacarsen, failed to reduce cardiovascular events despite lowering harmful cholesterol levels. This setback raises concerns about the efficacy of similar treatments, including Eli Lilly's experimental Lp(a) drug.
Eli Lilly's stock hits all-time high after EMA recommends Jaypirca for CLL treatment.
Eli Lilly's stock reached an all-time high following the European Medicines Agency's (EMA) advisory committee recommendation to approve Jaypirca (pirtobrutinib) for treating adults with chronic lymphocytic leukemia (CLL) across all lines of therapy. Additionally, the availability of Lilly's obesity drugs, Zepbound and Foundayo, through Medicare at $50 per month starting July 1, 2026, further bolstered investor confidence.
Analyze any chart in seconds
This is today's read on Eli Lilly. Point your camera at any chart and ChartDetector AI gives you a full technical analysis in seconds — free on iPhone and Android.
AI-generated from public news sources. Not financial advice.
